RONALD ASBURY ANDREWS
CIK 1299153 · Former CEO · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$361.6K
Companies
7
Total Filings
61
Lifetime Open-Market Net
$43.28M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PSTV | Director | 922 | $3.76 | $3.5K | $0 | 2 | 2026-07-01 |
| PRPO | Director | 15,796 | $22.67 | $358.1K | $0 | 18 | 2026-01-20 |
| Insight Molecular Diagnostics Inc. (OCX) Delisted | Former CEO | 29,161 | $3.20 | $93.3K | $43.07M | 15 | 2022-12-09 |
| Oxford Immunotec Global PLC (OXFD) Delisted | Director | 4,081 | — | — | $0 | 6 | 2020-06-26 |
| LIFE | President, Medical Sciences | 0 | $18.80 | $0 | $154.8K | 7 | 2014-02-04 |
| CLARIENT, INC (CLRT) Delisted | Vice-Chairman and CEO | 0 | — | — | $53.0K | 7 | 2010-12-23 |
| Cardiac Science CORP (CSCX) Delisted | Director | 0 | — | — | $0 | 5 | 2010-12-06 |
Recent Filings · Page 2 of 7
61 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-06 | PRPO | Mixed | — | $0 | EDGAR |
| 2024-07-16 | PRPO | Grant (A) | +2,157 | $10.0K | EDGAR |
| 2024-06-25 | PRPO | Grant (A) | — | $0 | EDGAR |
| 2024-04-17 | PRPO | Grant (A) | +3,153 | $21.0K | EDGAR |
| 2023-10-26 | PRPO | Grant (A) | +4,005 | $0 | EDGAR |
| 2023-09-14 | PRPO | Grant (A) | +6,060 | $0 | EDGAR |
| 2023-01-10 | PRPO | Grant (A) | — | $0 | EDGAR |
| 2022-12-09 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Mixed | +250,000 | $0 | EDGAR |
| 2022-08-18 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +40,000 | $38.4K | EDGAR |
| 2022-03-17 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.